155 related articles for article (PubMed ID: 32589926)
41. Heating treatments affect the thermal behaviour of doxorubicin loaded in PEGylated liposomes.
Perinelli DR; Cespi M; Bonacucina G; Rendina F; Palmieri GF
Int J Pharm; 2017 Dec; 534(1-2):81-88. PubMed ID: 28993166
[TBL] [Abstract][Full Text] [Related]
42. Practical aspects in size and morphology characterization of drug-loaded nano-liposomes.
Peretz Damari S; Shamrakov D; Varenik M; Koren E; Nativ-Roth E; Barenholz Y; Regev O
Int J Pharm; 2018 Aug; 547(1-2):648-655. PubMed ID: 29913218
[TBL] [Abstract][Full Text] [Related]
43. Advances in nano-delivery systems for doxorubicin: an updated insight.
Kanwal U; Irfan Bukhari N; Ovais M; Abass N; Hussain K; Raza A
J Drug Target; 2018 Apr; 26(4):296-310. PubMed ID: 28906159
[TBL] [Abstract][Full Text] [Related]
44. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
[TBL] [Abstract][Full Text] [Related]
45. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
Ling L; Ismail M; Du Y; Yao C; Li X
Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
[TBL] [Abstract][Full Text] [Related]
46. Stability and drug release studies of an antimycotic nanomedicine using HPLC, dynamic light scattering and atomic force microscopy.
Watanabe A; Takagi M; Murata S; Kato M
J Pharm Biomed Anal; 2018 Jan; 148():149-155. PubMed ID: 29028561
[TBL] [Abstract][Full Text] [Related]
47. Leakage kinetics of the liposomal chemotherapeutic agent Doxil: The role of dissolution, protonation, and passive transport, and implications for mechanism of action.
Russell LM; Hultz M; Searson PC
J Control Release; 2018 Jan; 269():171-176. PubMed ID: 29122661
[TBL] [Abstract][Full Text] [Related]
48. Simulation of Stimuli-Responsive and Stoichiometrically Controlled Release Rate of Doxorubicin from Liposomes in Tumor Interstitial Fluid.
Yamamoto E; Hyodo K; Suzuki T; Ishihara H; Kikuchi H; Kato M
Pharm Res; 2018 Mar; 35(5):103. PubMed ID: 29557075
[TBL] [Abstract][Full Text] [Related]
49. Drug delivery system based on dendritic nanoparticles for enhancement of intravesical instillation.
Qiu X; Cao K; Lin T; Chen W; Yuan A; Wu J; Hu Y; Guo H
Int J Nanomedicine; 2017; 12():7365-7374. PubMed ID: 29066888
[TBL] [Abstract][Full Text] [Related]
50. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil).
Tsukioka Y; Matsumura Y; Hamaguchi T; Koike H; Moriyasu F; Kakizoe T
Jpn J Cancer Res; 2002 Oct; 93(10):1145-53. PubMed ID: 12417045
[TBL] [Abstract][Full Text] [Related]
51. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
52. Chitosan Immobilization on Bio-MOF Nanostructures: A Biocompatible pH-Responsive Nanocarrier for Doxorubicin Release on MCF-7 Cell Lines of Human Breast Cancer.
Abazari R; Mahjoub AR; Ataei F; Morsali A; Carpenter-Warren CL; Mehdizadeh K; Slawin AMZ
Inorg Chem; 2018 Nov; 57(21):13364-13379. PubMed ID: 30351060
[TBL] [Abstract][Full Text] [Related]
53. Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery.
Tam YT; To KK; Chow AH
Colloids Surf B Biointerfaces; 2016 Mar; 139():249-58. PubMed ID: 26724466
[TBL] [Abstract][Full Text] [Related]
54. Near-infrared light remote-controlled intracellular anti-cancer drug delivery using thermo/pH sensitive nanovehicle.
Qin Y; Chen J; Bi Y; Xu X; Zhou H; Gao J; Hu Y; Zhao Y; Chai Z
Acta Biomater; 2015 Apr; 17():201-9. PubMed ID: 25644449
[TBL] [Abstract][Full Text] [Related]
55. Controlled release of doxorubicin from polyethylene glycol functionalized melanin nanoparticles for breast cancer therapy: Part I. Production and drug release performance of the melanin nanoparticles.
Ozlu B; Kabay G; Bocek I; Yilmaz M; Piskin AK; Shim BS; Mutlu M
Int J Pharm; 2019 Oct; 570():118613. PubMed ID: 31415880
[TBL] [Abstract][Full Text] [Related]
56. Comparison of Physicochemical Properties of Generic Doxorubicin HCl Liposome Injection with the Reference Listed Drug.
Maiti K; Bhowmick S; Jain P; Zope M; Doshi K; Rajamannar T
Anticancer Agents Med Chem; 2018; 18(4):597-609. PubMed ID: 29173186
[TBL] [Abstract][Full Text] [Related]
57. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
58. Synthesis and characterization of doxorubicin modified ZnO/PEG nanomaterials and its photodynamic action.
Hariharan R; Senthilkumar S; Suganthi A; Rajarajan M
J Photochem Photobiol B; 2012 Nov; 116():56-65. PubMed ID: 22982207
[TBL] [Abstract][Full Text] [Related]
59. MRI Monitoring of Tumor-Selective Anticancer Drug Delivery with Stable Thermosensitive Liposomes Triggered by High-Intensity Focused Ultrasound.
Kim HR; You DG; Park SJ; Choi KS; Um W; Kim JH; Park JH; Kim YS
Mol Pharm; 2016 May; 13(5):1528-39. PubMed ID: 26998616
[TBL] [Abstract][Full Text] [Related]
60. A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human.
Montanha MC; Howarth A; Mohamed DA; Loier E; Main L; Rösslein M; Delmaar C; Prina-Mello A; Siccardi M
Drug Deliv Transl Res; 2022 Sep; 12(9):2178-2186. PubMed ID: 35551629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
